Skip to main content
. 2013 Oct 22;305(12):E1473–E1482. doi: 10.1152/ajpendo.00354.2013

Fig. 6.

Fig. 6.

Arterial (A) and hepatic sinusoidal (B) insulin, arterial (C) and hepatic sinusoidal (D) glucagon, and arterial (E) and portal vein (F) glucagon-like peptide-1 (GLP-1) in the control and lixisenatide groups; n = 6/group. Data are means ± SE. *P < 0.05 between groups (main effect significant; dotted line indicates data points that differed on post hoc analysis).